Q-omics provides the consensus-scored C1D profile across patient tissues and cancer cell-line models. C1D expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, C1D is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, C1D RNA expression shows 19,279 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, HNSC, and ACC as cancer lineages where C1D shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C1D — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C1D survival associations across molecular data types. C1D RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C1D RNA expression–survival associations across cancer types. High C1D expression shows unfavorable associations in HNSC, ACC and LIHC, but favorable associations in KIRC, LUSC and MESO. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for C1D RNA expression.
This table summarizes C1D tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for C1D. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C1D shows lower tumor expression in KICH and THCA and higher tumor expression in HNSC, BLCA, LIHC and CHOL. The HNSC box plot shows higher C1D RNA expression in tumor versus normal tissue (log2 FC = +0.803, t-test p < 0.001).
This table shows molecular features associated with C1D in patient tissues and cancer cell lines. In patient samples, C1D shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, C1D RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and UPPER_AERODIGESTIVE_TRACT.
